Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Goldman

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute|February 20, 2003
Multidrug resistance: can new drugs help chemotherapy score against cancer?Bruce Goldman
Journal of the National Cancer Institute|December 5, 2003
For investigational targeted drugs, combination trials pose challengesBruce Goldman
Nature|February 3, 2007
Reproductive medicine: the first cutBruce Goldman
Journal of the National Cancer Institute|April 5, 2007
Taming a mutinous mutant: an errant receptor becomes a prime cancer targetBruce Goldman
Journal of the National Cancer Institute|June 17, 2004
Next generation of targeted radiotherapy drugs emerging from the clinical pipelineBruce Goldman
Journal of the National Cancer Institute|November 4, 2004
Good drug, bad luck: business, regulatory issues can create obstacles for drug developmentBruce Goldman
Journal of the National Cancer Institute|November 20, 2003
Combinations of targeted therapies take aim at multiple pathwaysBruce Goldman
Journal of the National Cancer Institute|October 17, 2002
Cancer vaccines: finding the best way to train the immune systemBruce Goldman
Nature Biotechnology|February 11, 2009
The cancer vaccine roller coasterBruce Goldman, Laura DeFrancesco
Clinical and Experimental Nephrology|March 23, 2021
Segmental membranous nephropathyHae Yoon Grace Choung, Bruce Goldman
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute|February 20, 2003
Multidrug resistance: can new drugs help chemotherapy score against cancer?Bruce Goldman
Journal of the National Cancer Institute|December 5, 2003
For investigational targeted drugs, combination trials pose challengesBruce Goldman
Nature|February 3, 2007
Reproductive medicine: the first cutBruce Goldman
Journal of the National Cancer Institute|April 5, 2007
Taming a mutinous mutant: an errant receptor becomes a prime cancer targetBruce Goldman
Journal of the National Cancer Institute|June 17, 2004
Next generation of targeted radiotherapy drugs emerging from the clinical pipelineBruce Goldman
Journal of the National Cancer Institute|November 4, 2004
Good drug, bad luck: business, regulatory issues can create obstacles for drug developmentBruce Goldman
Journal of the National Cancer Institute|November 20, 2003
Combinations of targeted therapies take aim at multiple pathwaysBruce Goldman
Journal of the National Cancer Institute|October 17, 2002
Cancer vaccines: finding the best way to train the immune systemBruce Goldman
Nature Biotechnology|February 11, 2009
The cancer vaccine roller coasterBruce Goldman, Laura DeFrancesco
Clinical and Experimental Nephrology|March 23, 2021
Segmental membranous nephropathyHae Yoon Grace Choung, Bruce Goldman
Pageof 4